期刊
INTERNAL MEDICINE JOURNAL
卷 41, 期 1B, 页码 90-101出版社
WILEY
DOI: 10.1111/j.1445-5994.2010.02340.x
关键词
empiric; neutropenic fever; beta-lactam monotherapy; systemic compromise; resistance
资金
- Victorian Integrated Cancer Services
- Victorian Department of Human Services
- Novartis
- Pfizer
- GlaxoSmithKline
- Schering-Plough
- Amgen
- Gilead
- Merck Sharp Dohme
- Roche
- Hospira
- Alphapharm
- Orphan
- Merck Serono
- Celgene
Administration of empiric antimicrobial therapy is standard practice in the management of neutropenic fever, but there remains considerable debate about the selection of an optimal regimen. In view of emerging evidence regarding efficacy and toxicity differences between empiric treatment regimens, and strong evidence of heterogeneity in clinical practice, the current guidelines were developed to provide Australian clinicians with comprehensive guidance for selecting an appropriate empiric strategy in the setting of neutropenic fever. Beta-lactam monotherapy is presented as the treatment of choice for all clinically stable patients while early treatment with combination antibiotic therapy is considered for patients at higher risk. Due consideration is given to the appropriate use of glycopeptides in this setting. Several clinical caveats, accounting for institution- and patient-specific risk factors, are provided to help guide the judicious use of the agents described. Detailed recommendations are also provided regarding time to first dose, timing of blood cultures, selection of a first-line antibiotic regimen, subsequent modification of antibiotic choice and cessation of therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据